(AOF) – Biosynex and Theradiag announce that their extraordinary general meetings met this Friday and approved the merger-absorption of Theradiag by Biosynex, on the basis of an exchange ratio of 1 Biosynex share for 7 Theradiag shares. The merger-absorption leading to the dissolution without liquidation of Theradiag took effect today. In application of the exchange parity, Biosynex today increased its share capital by a nominal amount of 4,582.6 euros by issuing 495,826 shares with a nominal value of 0.10 euros each.
The new shares will be issued and admitted to trading on Euronext Growth Paris on December 21, 2023 and allocated to Theradiag shareholders on December 27, 2023. Theradiag shares will be delisted on December 21, 2023.
The takeover project announced at the end of September is part of a process of rationalization of the Biosynex group with a desire to “create a world leader in biotherapy monitoring”.